EMERGING INFECTIOUS DISEASES RESEARCH PREVAIL I, III, V AND PREVAC MALI

新发传染病研究取得进展 I、III、V 和 PREVAC 马里

• 批准号: 10714518
• 负责人: CALVIN PROFFITT
• 金额: $ 482万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-16 至 2025-09-15
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10714518
• 关键词: Biological Assay; Biomedical Research; Data Analyses; Emerging Communicable Diseases; Funding; Infectious Diseases Research; Laboratories; Mali; National Institute of Allergy and Infectious Disease; Publications; Running; Sampling; Services; Technology; Work

PREVAIL I, PREVAIL III, and PREVAIL V remain incomplete, with inadequate funding remaining on current non-severable task orders to complete necessary laboratory work, data analyses, close-out activities, and publication of findings. DCR has requested the services of Leidos Biomedical Research, Inc. to oversee the completion of the studies under a new non-severable task order.

PREVAIL I、PREVAIL III和PREVAIL V仍未完成，目前不可分割的任务订单上剩余的资金不足，无法完成必要的实验室工作、数据分析、收尾活动和发表研究结果。 DCR已请求Leidos Biomedical Research，Inc.提供服务。监督根据新的不可分割的任务令完成的研究。